A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
Abstract Multiple myeloma is a prevalent hematologic cancer. This investigation analyzes the latest global, regional, and national data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. Data on the incidence, prevalence, disability-adjusted life years, and mortality rates of...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-83630-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594752152797184 |
|---|---|
| author | Qianru Hou Xinyang Li Huanxin Ma Di Fu Aijun Liao |
| author_facet | Qianru Hou Xinyang Li Huanxin Ma Di Fu Aijun Liao |
| author_sort | Qianru Hou |
| collection | DOAJ |
| description | Abstract Multiple myeloma is a prevalent hematologic cancer. This investigation analyzes the latest global, regional, and national data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. Data on the incidence, prevalence, disability-adjusted life years, and mortality rates of multiple myeloma, including estimates and 95% uncertainty intervals, were sourced from the 2021 Global Burden of Diseases Study. Furthermore, we explored the trends affecting the multiple myeloma burden from 1990 to 2021, breaking it down by demographic, age, and epidemiological factors. By 2021, the global incidence of multiple myeloma involved 148,754.63 reported cases, with confidence intervals ranging from 131,780.43 to 162,049.23. Worldwide, the number of mortality attributed to multiple myeloma reached 116,359.63, with the confidence interval lying between 103,078.62 and 128,470.57, and an age-standardized mortality rate of 1.37 per 100,000 individuals, the confidence interval for which was 1.22 to 1.52. There was a consistent increase in the incidence, prevalence, and disability-adjusted life years associated with multiple myeloma. Most of the disease burdens were seen in high income countries though its incidence is on the rise in low-income countries. Forecast for the years 2022–2050 showed the further increase in the incidence, prevalence, disability-adjusted life years, and age-standardized death rates of multiple myeloma. |
| format | Article |
| id | doaj-art-37344cee8d9c4aacb340d11734544ca5 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-37344cee8d9c4aacb340d11734544ca52025-01-19T12:21:11ZengNature PortfolioScientific Reports2045-23222025-01-0115111210.1038/s41598-024-83630-xA systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecastQianru Hou0Xinyang Li1Huanxin Ma2Di Fu3Aijun Liao4Department of Hematology, Shengjing Hospital of China Medical UniversityDepartment of General and Vascular Surgery, Shengjing Hospital, China Medical UniversityDepartment of Hematology, Shengjing Hospital of China Medical UniversityDepartment of Hematology, Shengjing Hospital of China Medical UniversityDepartment of Hematology, Shengjing Hospital of China Medical UniversityAbstract Multiple myeloma is a prevalent hematologic cancer. This investigation analyzes the latest global, regional, and national data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. Data on the incidence, prevalence, disability-adjusted life years, and mortality rates of multiple myeloma, including estimates and 95% uncertainty intervals, were sourced from the 2021 Global Burden of Diseases Study. Furthermore, we explored the trends affecting the multiple myeloma burden from 1990 to 2021, breaking it down by demographic, age, and epidemiological factors. By 2021, the global incidence of multiple myeloma involved 148,754.63 reported cases, with confidence intervals ranging from 131,780.43 to 162,049.23. Worldwide, the number of mortality attributed to multiple myeloma reached 116,359.63, with the confidence interval lying between 103,078.62 and 128,470.57, and an age-standardized mortality rate of 1.37 per 100,000 individuals, the confidence interval for which was 1.22 to 1.52. There was a consistent increase in the incidence, prevalence, and disability-adjusted life years associated with multiple myeloma. Most of the disease burdens were seen in high income countries though its incidence is on the rise in low-income countries. Forecast for the years 2022–2050 showed the further increase in the incidence, prevalence, disability-adjusted life years, and age-standardized death rates of multiple myeloma.https://doi.org/10.1038/s41598-024-83630-xGlobal burden of Disease StudyMultiple myelomaPublic healthMortality |
| spellingShingle | Qianru Hou Xinyang Li Huanxin Ma Di Fu Aijun Liao A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast Scientific Reports Global burden of Disease Study Multiple myeloma Public health Mortality |
| title | A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast |
| title_full | A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast |
| title_fullStr | A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast |
| title_full_unstemmed | A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast |
| title_short | A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast |
| title_sort | systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast |
| topic | Global burden of Disease Study Multiple myeloma Public health Mortality |
| url | https://doi.org/10.1038/s41598-024-83630-x |
| work_keys_str_mv | AT qianruhou asystematicepidemiologicaltrendsanalysisstudyinglobalburdenofmultiplemyelomaand29yearsforecast AT xinyangli asystematicepidemiologicaltrendsanalysisstudyinglobalburdenofmultiplemyelomaand29yearsforecast AT huanxinma asystematicepidemiologicaltrendsanalysisstudyinglobalburdenofmultiplemyelomaand29yearsforecast AT difu asystematicepidemiologicaltrendsanalysisstudyinglobalburdenofmultiplemyelomaand29yearsforecast AT aijunliao asystematicepidemiologicaltrendsanalysisstudyinglobalburdenofmultiplemyelomaand29yearsforecast AT qianruhou systematicepidemiologicaltrendsanalysisstudyinglobalburdenofmultiplemyelomaand29yearsforecast AT xinyangli systematicepidemiologicaltrendsanalysisstudyinglobalburdenofmultiplemyelomaand29yearsforecast AT huanxinma systematicepidemiologicaltrendsanalysisstudyinglobalburdenofmultiplemyelomaand29yearsforecast AT difu systematicepidemiologicaltrendsanalysisstudyinglobalburdenofmultiplemyelomaand29yearsforecast AT aijunliao systematicepidemiologicaltrendsanalysisstudyinglobalburdenofmultiplemyelomaand29yearsforecast |